EBV-associated lymphoproliferative disease post-CAR-T cell therapy  

作　　者：Shiyuan Zhang Xiaoxi Zhou Shangkun Zhang Na Wang Tongcun Zhang Donghua Zhang Qilin Ao Yang Cao Liang Huang 

机构地区：[1]Department of Hematology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province,Wuhan,430030,China [3]Institute of Biology and Medicine,College of Life and Health Sciences,Wuhan University of Science and Technology,Wuhan,430081,China [4]Department of Pathology,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430030,China [5]State Key Laboratory of Experimental Hematology,National Clinical Research Center for Blood Diseases,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin,300020,China [6]Tianjin Institutes of Health Science,Tianjin,301600,China

出　　处：《Frontiers of Medicine》2024年第2期394-398,共5页医学前沿（英文版）

基　　金：supported by the funding from the National Natural Science Foundation of China(No.82070211 to Dr.Liang Huang);the National Key R&D Program of China(No.2022YFC2502604 to Dr.Liang Huang).

摘　　要：Epstein–Barr virus(EBV)-associated lymphoproliferative diseases(EBV-LPDs)are common complications that occur after solid organ transplantation or allogeneic hematopoietic stem-cell transplantation(HSCT).However,their occurrence and treatment post-chimeric antigen receptor-modified T(CAR-T)cell therapy has not been reported.Two patients had been diagnosed with EBV-positive aggressive B-cell lymphoma and experienced relapses after multiple lines of treatment.After receiving CAR-T cell therapy in tandem with autologous HSCT,the patients achieved complete remission.However,with a median time of 38.5 months after CAR-T cell therapy,B-cell-derived EBV-LPDs were diagnosed,and they were relieved through the administration of immune checkpoint inhibitor or B-cell-depleting agents.Collectively,our report suggests that EBV-LPDs may represent a long-term adverse event after CAR-T cell therapy,especially in patients who previously had EBV-positive disorders,and they can be resolved by immune normalization strategy or B-cell depleting therapy.

关 键 词：EBV-associated lymphoproliferative disease chimeric antigen receptor T-cell autologous stem cell transplantation immune checkpoint inhibitor 

分 类 号：R551.2[医药卫生—血液循环系统疾病]